| Online-Ressource |
Verfasst von: | Hauswald, Henrik [VerfasserIn]  |
| Jensen, Alexandra [VerfasserIn]  |
| Krauß, Jürgen [VerfasserIn]  |
| Haselmann, Renate [VerfasserIn]  |
| Lossner, Karen [VerfasserIn]  |
| Münter, Marc [VerfasserIn]  |
| Debus, Jürgen [VerfasserIn]  |
Titel: | Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx |
Verf.angabe: | H. Hauswald, A. D. Jensen, J. Krauss, R. Haselmann, K. Lossner, S. Hartmann, C. Windemuth-Kieselbach, M. W. Münter, J. Debus |
E-Jahr: | 2018 |
Jahr: | November 2018 |
Umfang: | 10 S. |
Fussnoten: | Gesehen am 20.12.2018 |
Titel Quelle: | Enthalten in: Clinical and translational radiation oncology |
Ort Quelle: | Amsterdam : Elsevier, 2016 |
Jahr Quelle: | 2018 |
Band/Heft Quelle: | 13(2018), Seite 64-73 |
ISSN Quelle: | 2405-6308 |
Abstract: | Purpose: This phase II trial was designed to evaluate efficacy and safety of a highly intensified therapy in locally advanced squamous cell carcinoma of the oro-, hypopharynx and larynx. Methods: In this prospective, mono-centric, open-label, non-randomized phase II trial the single treatment arm consisted of a combined induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil, followed by bioradiation with the monoclonal antibody cetuximab, carbon ion boost (24Gy(RBE) in 8 fractions) and IMRT (50Gy in 25 fractions). The trial was closed early due to slow accrual. Results: Eight patients (median age 52.5years) were enrolled into the trial. The median follow-up was 13months and the 12-months locoregional tumor control, progression-free survival and overall survival rates were 100.0% each. Complete remission was achieved in 7 patients. The most commonly late radiation adverse event was xerostomia (85.7% at 12months). Five serious adverse events with recovery were documented in 4 patients: mucositis grade 3 (n=2), decreased lymphocyte count grade 4, febrile neutropenia grade 4 and hypersensitivity grade 3 to cetuximab (n=1 each). Most symptom scales had their worst value at the last treatment day and recovered until the 4th follow-up visit. Conclusion: The study treatment was tolerable and promising. Reduced quality of life recovered for most aspects until the last follow-up visit. |
DOI: | doi:10.1016/j.ctro.2018.09.005 |
URL: | kostenfrei: Volltext ; Verlag: http://dx.doi.org/10.1016/j.ctro.2018.09.005 |
| kostenfrei: Volltext: http://www.sciencedirect.com/science/article/pii/S240563081830065X |
| DOI: https://doi.org/10.1016/j.ctro.2018.09.005 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | Carbon ion therapy |
| Cetuximab |
| Head and neck cancer |
| LAHNC |
| Particle therapy |
| SCCHN |
K10plus-PPN: | 1585802867 |
Verknüpfungen: | → Zeitschrift |
|
|
| |
Lokale URL UB: | Zum Volltext |
Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx / Hauswald, Henrik [VerfasserIn]; November 2018 (Online-Ressource)